

## MARKET DATA

Symbol	IXS.V
Exchange	CDNX
Share Price	\$0.27
Shares Outstanding	N/A
Market Cap:	N/A

## RECENT DEVELOPMENTS

InNexus Biotechnology recently announced its first two candidates, DXL625 (CD20) targeting Non-Hodgkin's Lymphoma (NHL) and DXL702 (HER2/neu) for Breast Cancer. Both candidates have entered pre-clinical status with work ongoing.


InNexus has also recently completed the proof-of-concept and launched DXLdiagnostics™ and is readying a new transgenic mouse platform, DXLmouse™.

InNexus has presented its latest data at the AACR meeting in San Diego, California, highlighting achievements of DXL™ technology and its most recent animal studies.



### InNexus Biotechnology

13208 East Shea Boulevard, The Mayo Clinic Collaborative Research Building, Suite 200  
Scottsdale, AZ 85259  
(480) 862-7500  
[www.ixsbio.com](http://www.ixsbio.com)



**Jeff Morhet**  
Chairman & CEO

## PRODUCT AND PRODUCT CANDIDATE PIPELINE

**Name:** DXL625 (CD20)  
**Indication:** NHL  
**Description:** Anti-CD20 MAb  
**Status:** Preclinical

**Name:** DXLdiagnostics™  
**Indication:** Diagnostic Platform  
**Status:** Commercial

**Name:** DXL702(HER2/neu)  
**Indication:** Breast Cancer  
**Description:** Anti-HER2/neu  
**Status:** Preclinical

**Name:** DXLmouse™  
**Indication:** Transgenic Mouse Platform  
**Status:** Development

## Company Description

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit [www.ixsbio.com](http://www.ixsbio.com)